Atomo Diagnostics Limited (ASX:AT1)

Australia · Delayed Price · Currency is AUD

0.0120

-0.0020 (-14.29%)

Nov 10, 2026, 12:13 PM AEDT

Market Cap	10.83M -46.5%
Revenue (ttm)	5.33M +40.6%
Net Income	-3.51M
EPS	-0.00
Shares Out	902.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,836,775
Open	0.0145
Previous Close	0.0140
Day's Range	0.0120 - 0.0145
52-Week Range	0.0120 - 0.0480
Beta	1.26
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-testing programs; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia. [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2010

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol AT1

Full Company Profile

Financial Performance

In fiscal year 2026, Atomo Diagnostics's revenue was 5.33 million, an increase of 40.65% compared to the previous year's 3.79 million. Losses were -3.51 million, -29.32% less than in 2025.

Financial Statements

News

Atomo Diagnostics Transcript: AGM 2026

FY26 revenue reached AUD 5.3m, with 35% gross margin and year-end cash of AUD 3.7m. Priorities for FY27 include scaling HIV and OEM sales, improving margins, and advancing Syphilis and Gen 4 HIV toward launch in 18–24 months.

5 days ago - Transcripts

Atomo Diagnostics Slides: FY 2026

Atomo Diagnostics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 4, 2026.

5 days ago - Filings

Atomo Diagnostics Earnings Call Transcript: Q1 2027

Q1 revenue rose 140% YoY to AUD 1.63m, driven by HIV and OEM growth, while gross margin fell to 26% and EBITDA loss widened. Pipeline additions and manufacturing initiatives target broader revenue and improved margins.

7 days ago - Transcripts

Atomo Diagnostics Earnings release: Q1 2027

Atomo Diagnostics released its Q1 2027 earnings on November 2, 2026, summarizing the period's financial results.

7 days ago - Filings

Atomo Diagnostics Slides: Q1 2027

Atomo Diagnostics has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on November 2, 2026.

7 days ago - Filings

Atomo Diagnostics Earnings Call Transcript: H2 2026

FY26 revenue grew 41% to AUD 5.3m, with HIV and OEM streams expanding and underlying EBITDA improving 39%. FY27 priorities include margin recovery, cost discipline, and advancing the product pipeline.

6 weeks ago - Transcripts

Atomo Diagnostics Annual report: H2 2026

Atomo Diagnostics has published its H2 2026 annual report on September 23, 2026.

6 weeks ago - Filings

Atomo Diagnostics Slides: H2 2026

Atomo Diagnostics has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 23, 2026.

6 weeks ago - Filings

Atomo Diagnostics Earnings Call Transcript: Q4 2026

Revenue grew 40% year-over-year to AUD 5.3 million, driven by HIV and Pascal OEM segments, with strong cash position and no debt. Operational upgrades and new product launches in syphilis and liver tests are expected to support continued growth into FY 2027.

3 months ago - Transcripts

Atomo Diagnostics Slides: Q4 2026

Atomo Diagnostics has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 23, 2026.

3 months ago - Filings

Atomo Diagnostics Earnings Call Transcript: Q3 2026

Q3 marked a transformative period with strong sales momentum, a strengthened balance sheet, and key regulatory wins, notably the U.S. CLIA waiver for FebriDx. The company expects significant revenue growth in Q4 and continued expansion in HIV, syphilis, and liver function testing.

6 months ago - Transcripts